secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALX ONCOLOGY HOLDINGS INC (ALXO)
CIK:        0001810182
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0000950170-22-023194
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ALX Oncology Q3 net loss widens to $35.3M; secures $100M loan facility, extends cash runway to mid-2025
--------------------------------------------------------------------------------

- GAAP net loss $35.3M ($0.87/diluted share) vs $24.6M ($0.61) in Q3 2021; non-GAAP loss $29.1M vs $20.4M.
- Cash, equivalents, investments $293.1M; $100M term loan facility ($10M drawn) extends runway to mid-2025.
- R&D expenses $29.4M (up 62% YoY) on increased clinical trial costs; G&A $7.3M (up 14%).
- Initial Phase 1 ASPEN-05 AML data showed no MTD, full CD47 occupancy, anti-leukemic activity; ASH poster Dec 12, 2022.
- New clinical trial arms: I-SPY-P1 for HER2 breast cancer (evorpacept + ENHERTU); Phase 2 CRC trial first patient dosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810182/000095017022023194/0000950170-22-023194-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810182/000095017022023194/alxo-20221108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-023194

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer